YAR 1515Alternative Names: YAR-1515
Latest Information Update: 14 Jul 2016
At a glance
- Originator Yung-Jin Pharmaceutical
- Class Antiallergics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Rhinitis
Most Recent Events
- 30 Sep 2015 Launched for Rhinitis (unspecified route) before September 2015